An interventional study of Serranator Sonic Intravascular Lithotripsy (IVL) System in Peripheral Artery Disease, sponsored by Cagent Vascular LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Cagent Vascular LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this first-in-human study is to assess the safety and effectiveness of the Serranator Sonic Intravascular Lithotripsy (IVL) System™ for the treatment of peripheral artery disease.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
This study's planned enrollment of 30 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Browse Peripheral Arterial Disease studies →Cagent Vascular LLC is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
*Inclusion Criteria for Cohort A: ATK arm of the study:
Clinical:
Angiographic:
Subject has at least one patent tibial vessel on the target limb with runoff to the foot
Clinical:
Angiographic:
No or mild calcium present in the target lesion
Clinical:
Angiographic:
Calcification is at least moderate
Clinical:
Angiographic:
For blockages in the legs that occur above the knee.
Device: Serranator Sonic Intravascular Lithotripsy (IVL) System
For blockages in the legs that occur below the knee.
Device: Serranator Sonic Intravascular Lithotripsy (IVL) System
Serration remodeling balloon angioplasty with Intravascular Lithotripsy of the superficial femoral and popliteal arteries for Cohort A: Above-the-Knee; treatment of the infrapopliteal and inframalleolar arteries for Cohort B: Below-the-Knee.
Primary Safety: Major Adverse Events
Primary Safety: Major Adverse Events (MAE), measured at 30 days and defined as a composite of: * All cardiovascular death * Major amputation * Clinically-driven target lesion revascularization (CD-TLR)
Time frame: 30 Days
Primary Effectiveness: Procedural Success
Procedural Success, defined as: \<50% residual stenosis of the target lesion (with or without adjunctive PTA therapy and/or stenting) by angiographic core-lab assessment
Time frame: Procedure
Freedom from Major Adverse Events at 6 months
Freedom from Major Adverse Events, defined as a composite of all cardiovascular death, major amputation, and clinically-driven target lesion revascularization
Time frame: 6 months
Freedom from Major Adverse Events at 12 months
Freedom from Major Adverse Events defined as a composite of all cardiovascular death, major amputation, and clinically-driven target lesion revascularization.
Time frame: 12 months
Procedural success of ≤30% residual stenosis of the target lesion
Procedural success of ≤30% residual stenosis of the target lesion (with or without adjunctive PTA therapy and/or stenting) by angiographic core lab assessment
Time frame: Procedure
Patency rates of target lesion by duplex ultrasound
Patency rates at 30 days, 6 months, and 12 months of target lesion by duplex ultrasound. Target vessel patency by duplex ultrasound, defined as freedom from \> 50% restenosis, as assessed by duplex ultrasound peak systolic velocity ratio of ≥2.5
Time frame: 30 Days, 6 Months, and 12 Months
Freedom from clinically-driven target lesion revascularization
Freedom from clinically-driven target lesion revascularization (CD-TLR) at 30 days, 6 months, and 12 months
Time frame: 30 Days, 6 Months, and 12 Months
Change in Ankle-Brachial Index/Toe-Brachial Index
Change in Ankle-Brachial Index/Toe-Brachial Index (TBI) at 30 days, 6 months, and 12 months, as compared to baseline
Time frame: 30 Days, 6 Months, and 12 Months
Change in Rutherford Category
Change in Rutherford Category at 30 days, 6 months and 12 months, as compared to baseline
Time frame: 30 Days, 6 Months, and 12 Months
Change in Walking Impairment Questionnaire score
Change in Walking Impairment Questionnaire (WIQ) score at 30 days, 6 months and 12 months, as compared to baseline
Time frame: 30 Days, 6 Months, and 12 Months
Change in EuroQol-5D-3L
Change in EuroQol-5D-3L (EQ-5D-3L) at 30 days, 6 months and 12 months, as compared to baseline
Time frame: 30 Days, 6 Months, and 12 Months
No study locations are listed for this record.
Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 3 months is below that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cagent Vascular LLC